Video

Dr. Eskander on Combination Approaches With Immunotherapy in Ovarian Cancer

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the investigation of combinatorial approaches with immunotherapy in the treatment of patients with ovarian cancer.

Although single-agent immunotherapy has been largely ineffective, immunotherapy could still have a role in the space when used in combination with other already effective drugs, Eskander says. For example, combining checkpoint inhibitors with the antiangiogenic agent bevacizumab (Avastin) could hold promise. Researchers know that VEGF has an immune-inhibitory function, and that VEGF signaling leads to an increase in regulatory T cells and prevents effector T cells from migrating to the tumor microenvironment. Combining these mechanisms of action with standard chemotherapy might lead to better responses—and this is already being tested in ongoing studies.

Additionally, researchers are looking at combining immunotherapy with the 3 FDA-approved PARP inhibitors: rucaparib (Rubraca), olaparib (Lynparza), and niraparib (Zejula). PARP inhibitors are inciters of DNA damage and tumor-associated antigens. Could stimulating the tumor mutational burden cause the tumor to become immunogenic? Early data from the TOPACIO study suggested benefit, but the magnitude of this benefit remains unclear.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity